An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

May 31, 2038

Study Completion Date

May 31, 2038

Conditions
Achondroplasia
Interventions
DRUG

Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)

Trial Locations (16)

2145

The Children's Hospital at Westmead, Westmead

3052

Murdoch Children's Research Institute, Parkville

19803

Alfred I. duPont Hospital for Children, Wilmington

30033

Emory University, Decatur

45229

Cincinnati Childrens Hospital, Cincinnati

53226

Medical College of Wisconsin, Children's Hospital, Milwaukee

60611

Ann Robert and H. Lurie Children's Hospital of Chicago, Chicago

77030

Baylor College of Medicine, Houston

90509

Harbor - UCLA Medical Center, Torrance

94609

Children's Hospital & Research Center Oakland, Oakland

37232-2578

Vanderbilt University Medical Center, Nashville

565-0871

Osaka University, Osaka

330-8777

Saitama Children's Medical Center, Saitama

77-8503

Tokushima University Hospital, Tokushima

SE19RT

Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital, London

S102TH

Sheffield Children's NHS Foundation Trust, Sheffield

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY